CVS/$CVS
1D1W1MYTD1Y5YMAX
Capital at risk
About CVS
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates around 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 26 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
- Ticker
- $CVS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 259,500
- Headquarters
- Woonsocket, United States
- Website
- www.cvshealth.com
CVS Metrics
BasicAdvanced
$111B
22.65
$3.82
0.58
$2.66
3.08%
Price and volume
Market cap
$111B
Beta
0.58
52-week high
$110.68
52-week low
$69.51
Average daily volume
7.4M
Dividend rate
$2.66
Financial strength
Current ratio
0.866
Quick ratio
0.623
Long term debt to equity
0.907
Total debt to equity
0.955
Dividend payout ratio (TTM)
69.86%
Interest coverage (TTM)
3.92%
Profitability
EBITDA (TTM)
16,680
Gross margin (TTM)
13.64%
Net profit margin (TTM)
1.19%
Operating margin (TTM)
2.95%
Effective tax rate (TTM)
15.59%
Revenue per employee (TTM)
$1,590,000
Management effectiveness
Return on assets (TTM)
2.97%
Return on equity (TTM)
6.21%
Valuation
Price to earnings (TTM)
22.655
Price to revenue (TTM)
0.267
Price to book
1.39
Price to tangible book (TTM)
-3.63
Price to free cash flow (TTM)
9.361
Free cash flow yield (TTM)
10.68%
Free cash flow per share (TTM)
9.236
Dividend yield (TTM)
3.08%
Forward dividend yield
3.08%
Growth
Revenue change (TTM)
7.37%
Earnings per share change (TTM)
6.30%
3-year revenue growth (CAGR)
6.87%
10-year revenue growth (CAGR)
9.49%
3-year earnings per share growth (CAGR)
18.83%
10-year earnings per share growth (CAGR)
-1.29%
3-year dividend per share growth (CAGR)
4.81%
10-year dividend per share growth (CAGR)
5.55%
What the Analysts think about CVS
Analyst ratings (Buy, Hold, Sell) for CVS stock.
Analyst projections of the future price of CVS stock.
Bulls say / Bears say
Aetna’s turnaround is gaining traction. In the second quarter, its medical benefit ratio fell to 87.4% from 89.9%, adjusted operating income rose 85.5%, and CVS raised its full-year benefits guidance by more than $1 billion. (CVS Health, CNBC)
Cash generation is recovering, giving CVS more room to reduce leverage and return capital. The company produced $10.6 billion of operating cash flow in the first half, lifted its full-year target to at least $11.5 billion, and said it had repaid about $4 billion of debt by September. (CVS Health, StockAnalysis.com)
The recovery is broader than Aetna. In the second quarter, Health Services operating income increased 45% and Pharmacy and Consumer Wellness operating income nearly doubled, while all three segments beat revenue expectations; CVS is also using its pharmacy, clinics and app to capture demand for GLP-1 treatments. (Healthcare Dive, CNBC)
Caremark faces a tougher profit outlook: management expects client membership to fall in 2027, while moving away from rebate-based contracts could change the economics of the PBM business. The FTC settlement also requires clients to have an option to opt out of rebate payment models. (Reuters, Reuters)
Aetna’s improvement may not all be repeatable: CVS benefited from favourable prior-year cost development and from lapping a $471 million premium deficiency reserve. Management still warns that medical-cost trends remain elevated, leaving margins exposed if utilisation rises again. (CVS Health, CNBC)
The retail pharmacy arm remains exposed to weak underlying economics. CVS said regulatory price reductions, new generic drugs and pharmacy reimbursement pressure offset much of its revenue growth, while the segment’s sales were roughly flat in the second quarter. (CVS Health, Healthcare Dive)
Data summarised monthly by Lightyear AI. Last updated on 25 Sept 2026.
CVS Financial Performance
Revenues and expenses
CVS Earnings Performance
Company profitability
Upcoming events
CVS News
AllArticlesVideos
CVS Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CVS Health Corporation - CVS
Business Wire5 days ago
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga2 weeks ago
CVS Health's Aetna to streamline cancer treatment approvals
Reuters2 weeks ago
Funds containing CVS
AllEURUSDGBP
Fund name | Fund size | $CVS weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 1.81% |
iShares Dow Jones U.S. Select Dividend€EXX5 | €412M | 1.29% |
iShares Edge MSCI World Value Factor$IWVL | $7.4B | 0.72% |
iShares Edge MSCI World Value Factor€IS3S | €6.4B | 0.72% |
iShares Edge MSCI World Value Factor£IWFV | £5.5B | 0.72% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.